Gunilla Jerndal

AstraZeneca (Sweden)

Papers

1

Total Citations

11

H-Index

1

About

Gunilla Jerndal is a bioanalytical chemist whose work has advanced high-throughput methodologies for pharmaceutical analysis. Her primary research focuses on developing efficient sample preparation and chromatographic techniques for quantifying lipophilic compounds in biological matrices, particularly plasma. Her most notable contribution, detailed in a 2011 paper with 11 citations, introduces a direct injection method for lipophilic compounds from liquid–liquid extracted plasma samples onto reversed-phase columns. This approach offers a fast, robust alternative to conventional protein precipitation, addressing key challenges in bioanalysis by improving throughput and reducing sample handling complexity. While her citation count reflects a specialized impact, Jerndal’s work is valued for its practical utility in drug development and pharmacokinetic studies, where reliable quantification of lipophilic pharmaceuticals is critical. Her methodology has been adopted by researchers seeking efficient solutions for complex biological sample analysis, underscoring her role in streamlining bioanalytical workflows.

Research Focus

Key Achievements

1
H-Index
1
Papers
11
Total Citations
11
Avg Citations/Paper
🏆 Most Cited Paper
Direct Injection of Lipophilic Compounds in the Organic Phase from Liquid–Liquid Extracted Plasma Samples onto a Reversed-Phase Column
11 citations · 2011
📈 Most Prolific Year: 2011 (1 Papers)
🤝 Key Collaborators: 2
🏛 Institutions: AstraZeneca (Sweden)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago